21.09
+0.33%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Takeda Pharmaceutical Co Ltd ADR
Its shares trade under the ticker TAK. It has been listed since 27 October 2008. In the fiscal year to 31 March 2026, it reported revenue of $29.99bn and net income of $1.28bn. At that date it held total assets of $97.44bn and shareholders' equity of $49.02bn.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Oct 2008
- Employees
- 47,000
- Website
- takeda.com ↗
- Head office
- 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, M0, 103-8668
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Takeda's Entyvio and Gattex/Revestive address unmet needs in gastroenterology and rare diseases.
- Takeda's in-licensing agreements with BioMarin and GSK strengthen its rare disease portfolio.
- Takeda's global presence with 47,000 employees supports international market reach.
Weaknesses
- Takeda's reliance on US-listed ADR may limit investor access in certain markets.
- Takeda's product portfolio lacks significant presence in oncology and neuroscience segments.
- Takeda's collaboration with Neurocrine Biosciences may not yield immediate commercial benefits.
Opportunities
- Takeda's licensing agreement with Mirum Pharmaceuticals could expand its rare disease offerings.
- Takeda's collaboration with Seagen Inc. may enhance its oncology pipeline development.
- Takeda's partnership with Kyoto University (CiRA) could advance stem cell research applications.
Threats
- Takeda's dependence on in-licensing agreements with BioMarin and GSK poses supply chain risks.
- Takeda's limited focus on oncology may hinder growth in a high-demand market segment.
- Takeda's reliance on US-listed ADR could face regulatory challenges in international markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.